most active. Compounds 17–18 and 22–23 exhibited prominent antidiabetic as well as antioxidant activity. Compound 18 was considered a promising candidate for this series. The designed molecules were docked into α-glucosidase protein (PDB Code. 3TOP) to develop a correlation with the α-glucosidase inhibition studies and were also additionally docked into PPARγ proteins (PDB ID: 2PRG) with rosiglitazone
一种新颖的一系列ñ -甲基/苯甲基取代的
苯并咪唑基联对含有
2,4-噻唑烷二酮,
丙二酸二甲酯(
DMM)和
丙二酸二乙酯(D
EM) -取代的苄基类化合物17 - 27被设计,停靠,合成并评估其抗糖尿病活性研究。通过1 H NMR,13 C NMR,FTIR和质谱确认所有合成的化合物的结构。四种目标化合物(17 – 18和22 – 23)在4.10±0.01至9.12±0.06 µM的范围内显示出良好的抑制潜力。此外,合成化合物17– 27被评估其抗氧化潜力,并与标准
抗坏血酸进行比较,结果表明化合物18(
EC 50 = 0.176±0.002 mM)最具活性。化合物17 – 18和22 – 23表现出显着的抗糖尿病和抗氧化活性。化合物18被认为是该系列的有希望的候选人。将设计的分子对接至α-
葡萄糖苷酶蛋白(PDB代码3TOP)以发展与α-
葡萄糖苷酶抑制研究的相关性,另外还与
罗格列酮(标准药物)对接至
PPARγ蛋白(PDB